ArticlePloS one2017

Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma.

Bert H O'Neil et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.